Thus far, two IL-6Ris, biologic drugs specific for the IL-6 pathway and targeting soluble and membrane-bound IL6Rs, have been licensed for use in RA: the humanized mAb tocilizumab (TCZ) and the fully human mAb sarilumab. The gene discussed is IL6; the disease is rheumatoid arthritis.